NSE: GLAND | BSE: 543245

Strong Performer, Getting Expensive

Download real time

2060.70 -41.40 (-1.97%)

61.27% Gain from 52W Low

156.1K NSE+BSE Volume

NSE 30 Jul, 2025 3:31 PM (IST)

33,951.4

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Dividend

Gland Pharma Ltd. has an upcoming dividend of ₹18.00 per share due on 14 Aug 2025 See details

Gland Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAND, BSE:543245 Gland Pharma Ltd.

Search Inside the pdf :

Gland Pharma Ltd.

04 Feb 2025

2060.70

-1.97%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We maintain our HOLD rating with a target price of Rs 1,580, implying an upside potential of 4%, valuing the company at a PE of 20x for FY27.

Gland Pharma Ltd. has gained 45.85% in the last 3 Months

Gland Pharma Ltd.

03 Feb 2025

2060.70

-1.97%

New launches and higher milestone income drive margins

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (Gland) delivered a better-than-expected operating performance for the quarter. While revenue came in line, product mix and a higher share of milestone income led to better-than-expected margins in the base business.

Gland Pharma Ltd. has gained 15.68% in the last 1 Month

Gland Pharma Ltd.

05 Nov 2024

2060.70

-1.97%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

we maintain our HOLD rating with a target price of 1,760, implying an upside potential of ~9.4%, valuing the company at a PE of 26x for FY26.

Gland Pharma Ltd. has an average target of 1710.00 from 2 brokers.

Gland Pharma Ltd.

07 Aug 2024

2060.70

-1.97%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We have Hold on the stock

Gland Pharma Ltd. is trading above all available SMAs

Gland Pharma Ltd.

06 Aug 2024

2060.70

-1.97%

Lower milestone income and ROW sales hurt earnings

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) reported a miss on its 1QFY25 earnings, largely due to lower milestone income for the quarter. Further, postponement of the off-take of products by European customers hit 1QFY25 performance.

Gland Pharma Ltd. has gained 45.85% in the last 3 Months

Gland Pharma Ltd.

23 May 2024

2060.70

-1.97%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

Investing in capacity expansion through Capex reflects the company's commitment to meeting future demand and capturing new opportunities in the market. We have Hold on the stock

Gland Pharma Ltd. has gained 45.85% in the last 3 Months

Gland Pharma Ltd.

15 Feb 2024

2060.70

-1.97%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

China remains a key geographic focus area for the company. Gland has received and launched one product this year. Recommendation: HOLD

Number of FII/FPI investors increased from 203 to 212 in Jun 2025 qtr.

Gland Pharma Ltd.

08 Nov 2023

2060.70

-1.97%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

Stability in the Base Business; Maintain HOLD

Gland Pharma Ltd. has an average target of 1710.00 from 2 brokers.

Gland Pharma Ltd.

06 Nov 2023

2060.70

-1.97%

Slowly getting back on track

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma Ltd. has an average target of 1710.00 from 2 brokers.

Gland Pharma Ltd.

09 Aug 2023

2060.70

-1.97%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

Injectable companies (HIKMA, HOSIPORA, and Aurobindo) in the US market reported sales growth of ~4% YoY. We expect similar growth for GLAND in the core markets over a longer period and high single-digit growth in India and RoW over a long-term.

Gland Pharma Ltd. has gained 36.76% in the last 6 Months

VOTE: Is Gland Pharma Ltd. worth buying?

212 Votes:

Buy 81.13%

Sell 9.43%

Hold 9.43%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf